--- title: "Propanc Biopharma (PPCB) news: reverse split and delisting" url: "https://aibio.space/companies/propanc-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PPCB reverse split, delisting, going concern, offering, convertible notes and Nasdaq notice news: Propanc Biopharma faces Nasdaq delisting on bid price…" --- PPCB Propanc Biopharma, Inc. NASDAQ · Australia # Propanc Biopharma (PPCB) news PPCB reverse split, delisting and going concern news Listings · 2026-10-29 ## [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Nasdaq gave Propanc no 180-day compliance period because it reverse split within the past year. The company says it will appeal by October 30, 2026. Its fiscal 2026 net loss was $18.9 million. ## Latest Propanc Biopharma news 1. 2026-01-07 Listings [Propanc Biopharma gets Nasdaq minimum bid price deficiency notice, has until June 30, 2026](https://aibio.space/news/propanc-biopharma-gets-nasdaq-minimum-bid-price-deficiency-notice-has/) Propanc Biopharma received a Nasdaq notice that its stock has been below the $1.00 minimum bid price, and it has until June 30, 2026 to regain compliance. Its latest annual report showed cash of $12,088 at June 30, 2025. 2. 2025-08-18 Financings [Propanc Biopharma prices $4 million offering and moves to Nasdaq](https://aibio.space/news/propanc-biopharma-prices-4-million-offering-moves-nasdaq/) Propanc sold 1,000,000 shares at $4.00 each, while its prospectus carries a going-concern warning and reports $50,760 of cash on March 31, 2025. The stock left the OTC Pink market for the Nasdaq Capital Market. 3. 2025-07-30 Debt Financing [Propanc Biopharma sells $112,350 convertible note for $107,000, with 22% annual interest](https://aibio.space/news/propanc-biopharma-sells-112-350-convertible-note-107-000-22-percent/) Propanc Biopharma sold a $112,350 convertible note to 1800 Diagonal Lending LLC for $107,000. The note bears 22% interest, matures April 30, 2026 and converts at a 25% discount after 180 days, in a stock its last annual report says was quoted at $0.0003. ## Propanc Biopharma at a glance - **Ticker**: PPCB - **Listing**: NASDAQ - **Country**: Australia - **Cash, Mar 31, 2023**: $93,241 ### Related companies - [Amplia Therapeutics](https://aibio.space/companies/amplia-therapeutics/) ASX: ATX - [Cambium Bio](https://aibio.space/companies/cambium-bio/) ASX: CMB - [Polynovo](https://aibio.space/companies/polynovo/) ASX: PNV - [AdAlta](https://aibio.space/companies/adalta/) ASX: 1AD - [Biotron](https://aibio.space/companies/biotron/) ASX: BIT - [Curvebeam AI](https://aibio.space/companies/curvebeam-ai/) ASX: CVB - [Mesoblast](https://aibio.space/companies/mesoblast/) ASX: MSB - [Holista Colltech](https://aibio.space/companies/holista-colltech/) ASX: HCT ### Also on NASDAQ - [AETHLON MEDICAL INC](https://aibio.space/companies/aethlon-medical/) AEMD - [Apyx Medical](https://aibio.space/companies/apyx-medical/) APYX - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) MNPR - [Curis](https://aibio.space/companies/curis/) CRIS - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) XERS ## What Propanc Biopharma does Propanc Biopharma, Inc. is a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors using pancreatic proenzymes that target cancer stem cells in patients with pancreatic, ovarian and colorectal cancers. Its lead product candidate, PRP, is an intravenous injection combining two proenzymes, trypsinogen and chymotrypsinogen, in a synergetic ratio. The text says PRP is designed to treat early-stage cancer and pre-cancerous diseases, and as a preventative measure for patients at risk of cancer based on genetic screening. The company says it has conducted successful pre-clinical studies on PRP and has begun preparing a clinical study in advanced cancer patients. It plans to submit a clinical trial application in the fourth quarter of 2026 and, subject to raising additional capital, to start a First-In-Human Phase Ib study in the first half of 2027. PRP received FDA Orphan Drug Designation for pancreatic cancer in June 2017. Its POP1 joint research program, with the universities of Jaén and Granada, is designed to produce a backup clinical compound to PRP. | Product or program | What it is | Stage | |---|---|---| | PRP | Intravenous combination of trypsinogen and chymotrypsinogen proenzymes for cancer | Pre-clinical studies completed; clinical study being prepared | | POP1 Program | Joint research and drug discovery program for a backup clinical compound to PRP | Research program | Summarised from the company's [10-K filed Sep 25, 2026](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/form10-k.htm). ## Propanc Biopharma annual financials | Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 | |---|---|---| | Research and development | [$625,477](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/) | [$223,721](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/) | | Net income (loss) | [-$18.9 million](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/) | [-$58.9 million](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/) | | Cash from operations | [-$5.7 million](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/) | [-$405,168](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/) | Latest balance sheet, Mar 31, 2023 (10-Q): cash and equivalents $93,241. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Propanc Biopharma Did Propanc Biopharma do a reverse stock split? Our latest story on this, dated Oct 29, 2026: "Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/). Was Propanc Biopharma delisted? Our latest story on this, dated Oct 29, 2026: "Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/). Has Propanc Biopharma issued a going-concern warning? Our latest story on this, dated Aug 18, 2025: "Propanc Biopharma prices $4 million offering and moves to Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/propanc-biopharma-prices-4-million-offering-moves-nasdaq/). Has Propanc Biopharma raised money recently? Our latest story on this, dated Aug 18, 2025: "Propanc Biopharma prices $4 million offering and moves to Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/propanc-biopharma-prices-4-million-offering-moves-nasdaq/). Has Propanc Biopharma sold convertible notes? Our latest story on this, dated Jul 30, 2025: "Propanc Biopharma sells $112,350 convertible note for $107,000, with 22% annual interest". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/propanc-biopharma-sells-112-350-convertible-note-107-000-22-percent/). Has Propanc Biopharma received a Nasdaq deficiency notice? Our latest story on this, dated Jan 7, 2026: "Propanc Biopharma gets Nasdaq minimum bid price deficiency notice, has until June 30, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/propanc-biopharma-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). What is the ticker symbol of Propanc Biopharma? Propanc Biopharma, Inc. trades under the ticker PPCB on NASDAQ. Where is Propanc Biopharma listed? Propanc Biopharma, Inc. is listed on NASDAQ. What is the SEC CIK of Propanc Biopharma? The SEC Central Index Key (CIK) for Propanc Biopharma, Inc. is 1517681. Its filings are on SEC EDGAR. How many shares does Propanc Biopharma have outstanding? 6,331,116 shares as of 2026-09-23, per the cover page of its 10-K filed 2026-09-25. Which country or territory is Propanc Biopharma listed under? Our directory records Propanc Biopharma, Inc. under Australia. What does Propanc Biopharma do? Our directory classifies Propanc Biopharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Propanc Biopharma? The ISIN recorded for Propanc Biopharma, Inc. is US74346N8002. Does aibio.space cover Propanc Biopharma? aibio.space lists Propanc Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Propanc Biopharma incorporated? SEC records list its state or country of incorporation as DE. ## Investor discussion: Propanc Biopharma Members talk about Propanc Biopharma (PPCB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Propanc Biopharma, newest first. Each line links the filing it comes from. 1. 2026-10-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315226049298/form8-k.htm) 2. 2026-10-05 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315226045770/forms-1.htm) 3. 2026-07-17 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315226033807/forms-1.htm) 4. 2026-04-10 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315226016228/forms-1.htm) 5. 2026-02-02 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315226004792/forms-1.htm) 6. 2026-01-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315226000834/form8-k.htm) 7. 2025-12-30 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315225029472/forms-1.htm) 8. 2025-10-14 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1517681/000149315225018054/form8-k.htm) 9. 2025-08-18 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1517681/000164117225024613/form424b4.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PPCB on TradingView](https://www.tradingview.com/symbols/NASDAQ-PPCB/). ## SEC filings and registration - **SEC name**: Propanc Biopharma, Inc. - **CIK**: 1517681 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PPCB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: June 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 302/6 BUTLER STREET, CAMBERWELL, VICTORIA, Australia, 3124 - **Phone**: 61-03-9882-0780 - **Shares outstanding**: 6,331,116 as of 2026-09-23 (10-K filed 2026-09-25) - **Former names**: Propanc Health Group Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [S-1](https://www.sec.gov/Archives/edgar/data/1517681/000149315226045770/forms-1.htm) filed 2026-10-05 - [10-K](https://www.sec.gov/Archives/edgar/data/1517681/000149315226044373/form10-k.htm) filed 2026-09-25 - [S-1](https://www.sec.gov/Archives/edgar/data/1517681/000149315226033807/forms-1.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1517681/000149315226033173/form8-k.htm) filed 2026-07-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1517681/000149315226023210/form10-q.htm) filed 2026-05-14 - [S-1](https://www.sec.gov/Archives/edgar/data/1517681/000149315226016228/forms-1.htm) filed 2026-04-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/form8-k.htm) filed 2026-02-26 - [10-Q](https://www.sec.gov/Archives/edgar/data/1517681/000149315226007052/form10-q.htm) filed 2026-02-17 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001517681), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Propanc Biopharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PPCB, recorded under Australia. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Propanc Biopharma, Inc. - **Ticker**: PPCB - **Listing**: NASDAQ - **Country or territory**: Australia - **Business scope**: Biotechnology - **ISIN**: US74346N8002 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PPCB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/propanc-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Propanc Biopharma (PPCB) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/propanc-biopharma/